Biobanks Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Biobanking Market Report is Segmented by Equipment (Cryogenic Storage Systems [Refrigerators, Freezers, Ice Machines], Alarm and Monitoring Systems, Media & Consumables), Application (Regenerative Medicine, Drug Discovery, and More), Ownership Type (Public/Government, Academic/Non-profit and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Biobanking Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Biobanking Market with other markets in Healthcare Industry

Biobanking Market Analysis by Mordor Intelligence

The Biobanking Market size is estimated at USD 55.35 billion in 2025, and is expected to reach USD 70.61 billion by 2030, at a CAGR of 4.99% during the forecast period (2025-2030).

Expansion reflects the move from building sample repositories to supporting precision-medicine pipelines that merge stem-cell therapies, proteomics, and multi-omics workflows. Clearer regulations, such as the FDA’s January 2025 draft guidance on donor eligibility, are reducing clinical uncertainty and accelerating adoption in hospital and pharmaceutical settings. Demand is further lifted by hospital uptake of cord-blood services, public and private funding for pandemic preparedness, and the rise of AI-based quality analytics. Competitive intensity is moderate, with large suppliers acquiring niche innovators to offer integrated cold-chain, automation, and analytic platforms.

Key Report Takeaways

  • By application, regenerative medicine led with 36.47% revenue share in 2024; it is also projected to record the fastest 7.16% CAGR to 2030. 
  • By equipment, cryogenic storage systems held 48.58% of the biobanking market size in 2024; freezers are on track for a 7.96% CAGR during the forecast period. 
  • By ownership model, public and government entities commanded 39.73% share of the biobanking market in 2024; academic and non-profit biobanks are the fastest-growing group at 9.59% CAGR. 
  • By geography, North America dominated with a 36.31% share in 2024, yet Asia-Pacific is the fastest-growing region at a 10.03% CAGR to 2030.

Segment Analysis

By Equipment: Automation Drives Infrastructure Evolution

Cryogenic storage systems generated the most significant portion of 48.58% in the biobanking market size for equipment in 2024. End users are migrating towards freezers that achieve tighter temperature uniformity and lower energy draw, sustaining a robust 7.96% CAGR. Vendors such as Haier Biomedical introduced wide-neck models with dual-coolant redundancy and touchscreen diagnostics. Alarm and monitoring platforms represent the quickest-moving subsegment because regulators now expect continuous data logging. The arrival of SPT Labtech’s pneumatic arktic XC system reduces manual handling, raising throughput without compromising traceability.

Storage accessories are also evolving. Densely stacked racking and laser-etched barcodes help academic centres squeeze capacity from existing footprints. Mechanical ultra-low freezers offering ±5 °C uniformity are gaining favor as facilities attempt to lower nitrogen usage. Collectively, these shifts point to an equipment landscape where hardware, software and analytics converge, elevating entry requirements for new suppliers and reshaping competition inside the biobanking market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Application: Regenerative Medicine Leads Dual Growth

Regenerative medicine controlled 36.47% of 2024 revenue and matches that dominance with the fastest 7.16% CAGR through 2030. Drug-discovery applications follow, boosted by collaborations like Thermo Fisher’s proteomics work with the UK Biobank. Disease-surveillance programmes are adopting large-scale sample libraries to map outbreak dynamics, anchoring steady growth. The Tianjin Cord Blood Bank’s cure for aplastic anaemia after 19 years of storage shows that older archives retain high therapeutic value.

Future-oriented programmes, including ARPA-H’s PRINT for 3D-printed organs, create fresh sample requirements. Biobanks hence pivot toward integrated pipelines serving lab-bench discovery and bedside therapy alike. This convergence raises average revenue per sample and extends value chains inside the biobanking market.

By Ownership Type: Academic Sector Accelerates Innovation

Public and government operators generated 39.73% of revenue in 2024, owing to long-established repositories and stable funding. Academic and non-profit centres show the quickest 9.59% CAGR on the back of university-industry alliances. Harvard’s Longevity Study banks multifaceted ageing biomarkers, and Germany’s Biobank Alliance links 16 institutions to field 900,000 biosample queries. Private players continue to carve niches in newborn screening, personalised medicine, and logistics services.

Hybrid models are spreading, with public entities hosting base infrastructure while private partners scale analytical platforms. This collaborative fabric diversifies revenue sources, cushions funding cycles and stimulates healthy competition in the biobanking market ecosystem.

Biobanking Market: Market Share by Ownership Type
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America generated 36.31% of global revenue in 2024, anchored by FDA guidelines that provide a clear compliance path and by multi-billion-dollar capital commitments from major suppliers. Thermo Fisher is investing USD 2 billion to reinforce domestic cold-chain and analytical production. ATCC’s USD 87 million BARDA contract underscores federal support for pandemic-ready repositories.Continued precision-medicine roll-outs in Canada and heightened clinical-trial activity in Mexico sustain regional sample demand, bolstering revenues for the biobanking market.

Europe’s harmonised regulatory approach under Regulation 2024/1938 is stimulating cross-border projects such as the EUR 45 (USD 52) million Genome of Europe initiative. The UK Biobank’s 200,000-genome release cements its status as a flagship data resource. Germany’s federated network processes thousands of requests against 900,000 stored biospecimens, setting a benchmark for operational transparency. Southern European countries leverage EU funding to upgrade freezer capacity and digital-consent tools, broadening sample accessibility across the broader biobanking market.

Asia-Pacific is advancing at a 10.03% CAGR, the fastest worldwide. China plans to relax genetic-resource export rules, encouraging multinational R&D partnerships. National cord-blood treatments escalated to nearly 40,000 cases in 2024, proving clinical readiness for banked therapies. Japan remains a leader in allogeneic cord-blood transplants, and SK pharmteco’s USD 260 million Korean facility will expand GMP-grade storage capacity. Australia and South Korea strengthen regional momentum through strong ethics frameworks and translational-research programmes, collectively propelling the biobanking market.

Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The biobank market is moderately competitive. A few major players dominate some segments, while others are distributed among multiple players. Large technology vendors are consolidating capabilities to offer end-to-end workflows. Thermo Fisher’s USD 3.1 billion acquisition of Olink enhances proteomics, while the USD 4.1 billion Solventum filtration deal extends upstream bioprocessing. BD partners with Hamilton to integrate automated single-cell sorting into multi-omics pipelines. Cryoport’s takeover of TEC4MED and Bluebird Express gives it 675 active clinical-trial logistics contracts across 17 countries.

Specialists create value by focusing on diversity and decentralisation. Galatea Bio raised USD 25 million to chart genetic diversity in 10 million participants, offering prized datasets for pharma alliances. Johns Hopkins advocates a hybrid model where regional repositories feed into centralised analytics, mitigating diversity gaps seen during COVID-19. Technology differentiation now hinges on AI-driven integrity scoring and blockchain consent networks that optimise chain-of-custody while reducing data silos. These innovations intensify competition yet expand overall capabilities, reinforcing sustainable growth for the biobanking market.

Biobanking Industry Leaders

  1. Hamilton Company

  2. Thermo Fisher Scientific Inc.

  3. Avantor Inc. (VWR)

  4. BioLife Solutions Inc.

  5. Merck KGaA

  6. *Disclaimer: Major Players sorted in no particular order
Biobanking Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2025: Astoriom expanded its sample stability storage capabilities at its Tramore site in Ireland, enhancing offerings for scalable, regulatory-compliant storage solutions ranging from -60°C to -196°C following acquisitions of MTS Cryo Stores and Cool Repair Scientific UK.
  • May 2025: BD launched the FACSDiscover A8 Cell Analyzer, featuring breakthrough spectral and real-time cell imaging technologies that enable analysis of up to 50 characteristics of a single cell, enhancing biomarker discovery capabilities.
  • April 2025: Thermo Fisher Scientific announced a USD 2 billion investment in U.S. innovation and manufacturing over four years, including USD 1.5 billion for capital expenditures and USD 500 million for R&D to strengthen healthcare supply chains.
  • March 2025: Teknova and Pluristyx launched the proprietary PluriFreeze cryopreservation system designed to accelerate cell therapy development through enhanced preservation techniques.

Table of Contents for Biobanking Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Innovations in Regenerative Medicine
    • 4.2.2 Growing Incidences of Chronic Diseases
    • 4.2.3 Advances in Drug Discovery & Development
    • 4.2.4 Government & NGO Funding Inflows
    • 4.2.5 AI-Driven Sample-Quality Analytics Adoption
    • 4.2.6 Decentralized Blockchain-Enabled Consent Networks
  • 4.3 Market Restraints
    • 4.3.1 Complex & Evolving Regulatory Regimes
    • 4.3.2 High Total Ownership Cost of Cryogenic Infrastructure
    • 4.3.3 Litigation Over Donor Privacy & Data Ownership
    • 4.3.4 Liquid-Nitrogen Price Volatility
  • 4.4 Porter’s Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitutes
    • 4.4.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value in USD)

  • 5.1 By Product
    • 5.1.1 Cryogenic Storage Systems
    • 5.1.1.1 Refrigerators
    • 5.1.1.2 Freezers
    • 5.1.1.3 Ice Machines
    • 5.1.2 Alarm & Monitoring Systems
    • 5.1.3 Media & Consumables
  • 5.2 By Application
    • 5.2.1 Regenerative Medicine
    • 5.2.2 Drug Discovery
    • 5.2.3 Disease & Epidemiology Research
    • 5.2.4 Life-Science & Genomic Research
  • 5.3 By Ownership Type
    • 5.3.1 Public/Government
    • 5.3.2 Academic/Non-profit
    • 5.3.3 Private & Commercial
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Thermo Fisher Scientific Inc.
    • 6.3.2 Becton, Dickinson & Company
    • 6.3.3 Merck KGaA
    • 6.3.4 BioLife Solutions Inc.
    • 6.3.5 Hamilton Company
    • 6.3.6 Avantor Inc. (VWR)
    • 6.3.7 Tecan Group Ltd.
    • 6.3.8 STEMCELL Technologies
    • 6.3.9 CENTOGENE N.V.
    • 6.3.10 Bio-Techne Corp.
    • 6.3.11 Azenta Life Sciences
    • 6.3.12 Cryoport Inc.
    • 6.3.13 QIAGEN N.V.
    • 6.3.14 BioIVT
    • 6.3.15 Chart Industries
    • 6.3.16 Coriell Institute for Medical Research
    • 6.3.17 UK Biobank
    • 6.3.18 China Cord Blood Corp.
    • 6.3.19 Biovault Family
    • 6.3.20 Precision Cellular Storage

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Biobanking Market Report Scope

As per the scope of the report, a biobank is a biorepository where various biomaterials (usually human specimens) are stored for research purposes. The biobanks market is segmented by equipment (cryogenic storage systems (refrigerators, ice machines, and freezers), alarm monitoring systems, and other equipment), sample type (human tissue biobanking, stem cell biobanking, cord biobanking, DNA/RNA biobanking, and other services), application (regenerative medicine, drug discovery, and disease research), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.

By Product Cryogenic Storage Systems Refrigerators
Freezers
Ice Machines
Alarm & Monitoring Systems
Media & Consumables
By Application Regenerative Medicine
Drug Discovery
Disease & Epidemiology Research
Life-Science & Genomic Research
By Ownership Type Public/Government
Academic/Non-profit
Private & Commercial
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Product
Cryogenic Storage Systems Refrigerators
Freezers
Ice Machines
Alarm & Monitoring Systems
Media & Consumables
By Application
Regenerative Medicine
Drug Discovery
Disease & Epidemiology Research
Life-Science & Genomic Research
By Ownership Type
Public/Government
Academic/Non-profit
Private & Commercial
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current value of the biobanking market?

The market is valued at USD 55.35 billion in 2025 and is set to reach USD 70.61 billion by 2030.

Which segment shows both the largest share and the fastest growth?

Regenerative medicine accounts for 36.47% of revenue and leads growth with a 7.16% CAGR through 2030.

Why is Asia-Pacific considered the growth engine for biobanking?

Regional reforms that relax genetic-resource rules, rising cord-blood utilisation and major infrastructure projects together underpin a 10.03% CAGR for Asia-Pacific.

How are regulatory changes affecting global biobanking operations?

New standards in the EU, policy shifts in the United States and evolving rules in China require biobanks to update quality systems and invest in compliance, raising operating costs but improving safety.

What technologies are shaping the next phase of the biobanking market?

Automation, AI-driven sample-quality analytics, blockchain consent management and room-temperature DNA storage are the main technologies redefining workflows and lowering long-term costs.

Page last updated on: June 27, 2025

Biobanking Market Report Snapshots